nse,bse,nseindia,nse india,share price,stock price,stock value,shares prices,share prices,stock quote,stock prices, share prices, corporate announcements,board meetings,corporate actions,dividends,agm,stock split,bonus

Cipla Limited (NSE India Code : CIPLA) BUY

Company Name :

Enter Company Name or NSE Code

CIPLA Technical Levels

Resistance 2		388.25
Resistance 1		384.65
PIVOT		381.85
Support 1		378.25
Support 2		371.85

CIPLA Fundamentals

Earning Growth		17.47%
Profit Margin		15.77
PE		25.95
EPS		12.58
Quarter		30-Sep-11

CIPLA Futures

Close
Contracts Traded
Open Interest(OI)
Change in OI
Lot Size		1000

CIPLA Options

Most Active Call		380
Most Active Put		360
Highest OI Call		400
Highest OI Put		340
Expiry Date		19-Oct-12

CIPLA Technical Levels

Other Stocks from Pharmaceuticals Sector AARTIDRUGS ABBOTINDIA AJANTPHARM ALCHEM ALKALI ALPA AMRUTANJAN ANKURDRUGS ARL ASTRAZEN AUROPHARMA AVENTIS BALPHARMA BIOCON BLISSGVS CADILAHC CELESTIAL CIPLA DISHMAN DIVISLAB DRREDDY ELDERPHARM FDC FKONCO GLAXO GLENMARK GRANULES INDOCO INDSWFTLAB INDSWFTLTD IPCALAB JAGSNPHARM JBCHEPHARM JUBILANT KILITCH KOPRAN LUPIN LYKALABS MANGALAM MERCK MOREPENLAB NATCOPHARM NECLIFE NEULANDLAB OPTOCIRCUI ORCHIDCHEM PANACEABIO PARABDRUGS PFIZER PIRHEALTH

Sponsored Advertisement

CIPLA Share Price on 5-10-2012

Open		369.2
High		370.8
Low		320.3
Close		364.25
Volume		4565990
Change		-1.8 (-0.49%)

Series		EQ
Date of Listing		08-Feb-95
Paid Up Value		2
Face Value		2
Market Capital		18483.3 Crores
52 Week High/Low		395.4 / 276.15

Sponsored Advertisement

Cipla Limited Company Profile

Cipla has a product range comprising antibiotics, anti-bacterials, anti-asthmatics, anthelmintics, anti-ulcerants, oncology, corticosteroids, nutritional supplements and cardiovascular drugs. It is into anti-bacterial and anti-asthmatic segments and is the first player in Asia to launch non-CFC metered dose inhaler. DPCO coverage of Cipla is around 40 per cent. Exports grew by 30 per cent, exceeding Rs l0,500 million. Both active pharmaceutical ingredients (APIs) and formulations contributed to the growth in business in the international market. Overseas business forms 45 percent of the company`s total turnover. The company has its manufacturing facilities at Goa, Kurkumbh, Bangalore, Patalganga and Baddi. Cipla has been among the major suppliers of anti-malarial drugs and drugs for neglected diseases such as schistosomiasis to international markets. With the launch of Lamivudine, the company has become one of the few companies in the world to offer all three component drugs of retroviral combination therapy (zidovudine and stavudine already launched). The company plans to continue its R&D efforts with a major thrust on developing new products and delivery systems. It would also include patenting of newer processes/newer products/newer drug delivery systems/ newer medical devices/newer usage of drugs for both local and international markets. Development of agrotechnology, genetics and biotechnology for cultivation of medicinal plants and isolation of active ingredients from plant materials is also foreseen.

CIPLA Intraday Realtime Chart

CIPLA Corporate Announcements

DATE	PURPOSE
31-Jul-12	Updates
31-Jul-12	Press Release
31-Jul-12	Financial Result Updates
07-Jun-12	Dividend
07-Jun-12	Updates

CIPLA Corporate Actions

DATE	PURPOSE
01-Aug-12	Annual General Meeting And Dividend - Rs.2/- Per Share
01-Aug-12	AGM/DIV-RS.2/- PER SHARE
09-Aug-11	Annual General Meeting And Dividend Rs.2/- Per Share
09-Aug-11	AGM/DIV-RS.2/- PER SHARE

CIPLA Board Meetings

MEETING DATE	PURPOSE
31-Jul-12	Un-audited Financial Results
07-Jun-12	Results/Dividend
10-May-12	Un-audited Financial Results
13-Feb-12	Un-audited Financial Results
14-Nov-11	Un-audited Financial Results

CIPLA Related companies

Symbol	Company Name
AARTIDRUGS	Aarti Drugs Limited
ABBOTINDIA	Abbott India Limited
AJANTPHARM	Ajanta Pharma Limited
ALCHEM	Alchemist Limited
ALKALI	Alkali Metals Limited

Most Active NSE INDIA Stocks

HDFC LITL IVRCLINFRA HDIL UNITECH JPASSOCIAT GVKPIL TATAMOTORS IFCI IBREALEST ESSAROIL GMRINFRA BIRLAPOWER HINDALCO BHEL RENUKA RCOM DLF SUZLON RELCAPITAL IDFC ADANIENT ITC TATAPOWER BALLARPUR

Free Stock Market Tips:

What is a Letter of offer?

Home	Stock Market	IPO	Mutual Funds	Education	Paid Service
About us	Share Market	IPO Watch	MF News	IPO	Subscription
VJonDalalStreet	Technical Analysis	New IPO Review	Old Funds	Articles	Equity Performance
DalalStreet Blog	Stock Market News	Indian IPO News	New Funds	Stock Market	Futures Performance
Free Sms Alerts	World Stock Market	IPO Allotment Status	Best Funds	Financial Terms	Options Performance
Privacy	Stock Recommendations	Grey Market Premium	MF Analysis	Futures & Options	Jackpot Performance

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither VJonDalalStreet.com website nor any of its promoters shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes acceptance of our Disclaimer